Ligand Pharmaceuticals LGND Other — Total revenues and other income
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Ligand Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
The official record: Ligand Pharmaceuticals’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →
Ask your AI about Ligand Pharmaceuticals's other — total revenues and other income.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Ligand Pharmaceuticals's other — total revenues and other income?
- Ligand Pharmaceuticals (LGND) reported other — total revenues and other income of $681K in Q1 2026.
- How has Ligand Pharmaceuticals's other — total revenues and other income changed year-over-year?
- Ligand Pharmaceuticals's other — total revenues and other income increased by 48.0% year-over-year, from $460K to $681K.
- What is the long-term trend for Ligand Pharmaceuticals's other — total revenues and other income?
- Over 2 years (2023 to 2025), Ligand Pharmaceuticals's other — total revenues and other income has grown at a 112.3% compound annual growth rate (CAGR), from $1.05M to $4.73M.
- What does other — total revenues and other income mean?
- This metric measures the total financial receipts from financial royalties and other non-operating income streams attributed to the 'Other' segment. It reflects the company's success in leveraging its financial interest in third-party drug development and commercialization efforts. This data point is critical for evaluating the performance of the company's passive investment and royalty-based business model.